Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MXCT NYSE:PTN NYSE:RENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$2.15+1.4%$2.23$2.00▼$5.20$228.79M1.23613,383 shs436,971 shsPTNPalatin Technologies$0.09-44.6%$0.09$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shsRENXRelx$21.19$0.00$20.06▼$23.30N/AN/A100,590 shs547,934 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte+0.47%-5.78%-5.36%-18.77%-58.10%PTNPalatin Technologies0.00%0.00%0.00%+9,409,900.00%+9,409,900.00%RENXRelx0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMXCTMaxCyte2.9439 of 5 stars3.54.00.00.02.21.70.6PTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ARENXRelxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMXCTMaxCyte 3.00Buy$7.50248.84% UpsidePTNPalatin Technologies 0.00N/AN/AN/ARENXRelx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMXCTMaxCyte$37.68M6.07N/AN/A$1.95 per share1.10PTNPalatin Technologies$350K6.99N/AN/AN/A∞RENXRelxN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMXCTMaxCyte-$41.06M-$0.40N/AN/AN/A-110.92%-19.90%-17.24%8/5/2025 (Estimated)PTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ARENXRelxN/A$1.2217.37∞N/AN/AN/AN/AN/ALatest PTN, YGEN, MXCT, OSL, and RENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MXCTMaxCyte-$0.10N/AN/AN/A$9.57 millionN/A5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMXCTMaxCyteN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ARENXRelx$0.281.32%N/A22.95%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMXCTMaxCyteN/A12.2311.58PTNPalatin TechnologiesN/AN/AN/ARENXRelxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMXCTMaxCyte68.81%PTNPalatin Technologies11.50%RENXRelx1.37%Insider OwnershipCompanyInsider OwnershipMXCTMaxCyte3.30%PTNPalatin Technologies7.10%RENXRelxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMXCTMaxCyte80106.42 million102.90 millionOptionablePTNPalatin Technologies3026.01 millionN/AN/ARENXRelxN/AN/AN/ANot OptionablePTN, YGEN, MXCT, OSL, and RENX HeadlinesRecent News About These CompaniesK-9 Rex joins Springfield Township Police DepartmentJuly 17 at 6:33 AM | msn.comAccused Gilgo Beach serial killer Rex Heuermann set for hearing to resume over DNA evidenceJuly 17 at 6:33 AM | newsday.comNRex Masai: Police officer who claimed to be off-duty cornered as IPOA unleashes photographic evidenceJuly 17 at 6:33 AM | msn.comRex pick up ninth-straight win, 5-3July 16 at 11:46 PM | msn.comRex’s Morning Forecast - 7/16July 16 at 6:44 PM | wdam.comWRex postponed Tuesday nightJuly 16 at 6:44 PM | sports.yahoo.comRex’s Midday Forecast - 7/16July 16 at 6:44 PM | wdam.comWThe T Rex Came Alive Filming Jurassic ParkJuly 16 at 6:44 PM | msn.comRex Salisbury’s Cambrian Ventures raises new fund, bucking fintech slowdownJuly 16 at 6:44 PM | msn.comRex’s Morning Forecast - 7/15July 15 at 7:01 PM | wdam.comWInvincible VS - Official Rex Splode Gameplay TrailerJuly 15 at 7:01 PM | msn.comRex's Sunday game postponed, following 9-5 win SaturdayJuly 15 at 7:01 PM | sports.yahoo.comWas T.Rex Really A Hunter, Or Just A Giant Scavenger?July 15 at 7:01 PM | msn.comRex’s Midday Forecast - 7/15July 15 at 7:01 PM | wdam.comWDouglas (Doug) Rex DeWeeseJuly 15 at 7:01 PM | wcluradio.comWPreserved Blood Vessels Discovered in a Rib Bone from the World’s Largest T. Rex Could Shed Light on How Dinosaurs HealedJuly 15 at 7:01 PM | msn.comThe Selkirk Rex — Where Curls, Quirks, and Calm CollideJuly 15 at 1:01 PM | msn.comRandy Moss joked about Rex Ryan ahead of ESPN returnJuly 15 at 1:01 PM | msn.comIndependent adviser deems Rex Industry takeover offer ‘not fair and not reasonable’July 14 at 8:21 AM | thestar.com.myTOK, Could T Rex Really Swim? The Science Behind That Jurassic World Rebirth Scene Recycled From Jurassic Park, According To An ExpertJuly 14 at 3:08 AM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTN, YGEN, MXCT, OSL, and RENX Company DescriptionsMaxCyte NASDAQ:MXCT$2.15 +0.03 (+1.42%) Closing price 04:00 PM EasternExtended Trading$2.16 +0.01 (+0.47%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.Relx NYSE:RENXRELX NV, through its interest in RELX Group plc, provides information and analytics for professional and business customers across industries worldwide. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment offers information and analytics to institutions and professionals. The Risk & Business Analytics segment provides solutions and decision tools that combine public and industry specific content with technology and analytics to evaluate and predict risk, as well as enhance operational efficiency. The Legal segment offers legal, regulatory, and business information and analytics. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier NV and changed its name to RELX NV in June 2015. RELX NV was incorporated in 1880 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
